Picture of Avacta logo

AVCT Avacta Share Price

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapSucker Stock

Momentum

Relative Strength (%)
1m-43.15%
3m-55.03%
6m-61.96%
1yr-57.42%
Volume Change (%)
10d/3m+38.93%
Price vs... (%)
52w High-69.31%
50d MA-37.97%
200d MA-53.13%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-113.87%
Return on Equity-143.33%
Operating Margin-217.65%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Avacta EPS forecast chart

Profile Summary

Avacta Group plc is a life sciences company. The Company is focused on improving people's health and well-being through targeted oncology drugs and powerful diagnostics. It has two divisions: Diagnostics and Therapeutics. Its therapeutics division, which is a clinical-stage oncology drug developer, is building a wholly owned pipeline of novel Affimer immunotherapies and prelCISION tumour-targeted chemotherapies. Its lead program, AVA6000, is a prelCISION tumour-targeted form of the established chemotherapy doxorubicin. Its Affimer platform is a class of biotherapeutics based on a naturally occurring human protein. The Company’s prelCISION targeted chemotherapy platform releases active chemotherapy in the tumor, which limits the systemic exposure that causes damage to healthy tissues and thereby improves the overall safety and therapeutic potential of these anti-cancer treatments. The Company’s Diagnostics Division develops and supplies a range of in-vitro diagnostic (IVD) solutions.

Directors

Last Annual
December 31st, 2022
Last Interim
June 30th, 2023
Incorporated
April 29th, 2003
Public Since
September 8th, 2003
No. of Employees
120
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
gb flag iconLondon Stock Exchange
Shares in Issue
350,512,279

AVCT Share Price Performance

Upcoming Events for AVCT

Full Year 2023 Avacta Group PLC Earnings Release

Avacta Group PLC Annual Shareholders Meeting

Similar to AVCT

Picture of 4Basebio logo

4Basebio

gb flag iconLondon Stock Exchange

Picture of Allergy Therapeutics logo

Allergy Therapeutics

gb flag iconLondon Stock Exchange

Picture of Arecor Therapeutics logo

Arecor Therapeutics

gb flag iconLondon Stock Exchange

Picture of Batm Advanced Communications logo

Batm Advanced Communications

gb flag iconLondon Stock Exchange

Picture of Bioventix logo

Bioventix

gb flag iconLondon Stock Exchange

FAQ